BRPI0408704A - benzil-piridazinonas como inibidores de transcriptase reversa - Google Patents

benzil-piridazinonas como inibidores de transcriptase reversa

Info

Publication number
BRPI0408704A
BRPI0408704A BRPI0408704-6A BRPI0408704A BRPI0408704A BR PI0408704 A BRPI0408704 A BR PI0408704A BR PI0408704 A BRPI0408704 A BR PI0408704A BR PI0408704 A BRPI0408704 A BR PI0408704A
Authority
BR
Brazil
Prior art keywords
reverse transcriptase
formula
compounds
transcriptase inhibitors
pyridazinones
Prior art date
Application number
BRPI0408704-6A
Other languages
English (en)
Inventor
James Patrick Dunn
Brian William Dymock
Taraneh Mirzadegan
Eric Brian Sjogren
Steven Swallow
Zachary Kevin Sweeney
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0408704A publication Critical patent/BRPI0408704A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

"BENZIL-PIRIDAZINONAS COMO INIBIDORES DE TRANSCRIPTASE REVERSA". Esta invenção refere-se a derivados de piridazinonas inusitados, da fórmula I, onde R¬ 1¬-R¬ 4¬, R¬ 7¬, R¬ 8¬ e X¬ 1¬ são como definidos no sumário, e seus sais e solvatos farmaceuticamente aceitáveis, e métodos para inibir ou modular a trasncriptase reversa do Vírus da Imunodeficiência Humana (HIV) com compostos da fórmula I, composições farmacêuticas que contêm os compostos da fórmula I misturados com pelo menos um solvente, veículo ou excipiente, e processos para preparar compostos da fórmula I. Os compostos são úteis para tratar distúrbios nos quais HIV e vírus geneticamente relacionados estão implicados.
BRPI0408704-6A 2003-03-24 2004-03-17 benzil-piridazinonas como inibidores de transcriptase reversa BRPI0408704A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45714403P 2003-03-24 2003-03-24
PCT/EP2004/002736 WO2004085406A1 (en) 2003-03-24 2004-03-17 Benzyl-pyridazinons as reverse transcriptase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0408704A true BRPI0408704A (pt) 2006-03-07

Family

ID=33098202

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408704-6A BRPI0408704A (pt) 2003-03-24 2004-03-17 benzil-piridazinonas como inibidores de transcriptase reversa

Country Status (13)

Country Link
US (1) US7189718B2 (pt)
EP (1) EP1608629A1 (pt)
JP (1) JP4485520B2 (pt)
KR (1) KR20050119652A (pt)
CN (1) CN100469769C (pt)
AR (1) AR043674A1 (pt)
AU (1) AU2004224191A1 (pt)
BR (1) BRPI0408704A (pt)
CA (1) CA2518823A1 (pt)
MX (1) MXPA05010081A (pt)
RU (1) RU2344128C2 (pt)
TW (1) TW200505453A (pt)
WO (1) WO2004085406A1 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
ES2232306B1 (es) * 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
WO2005090317A1 (en) 2004-03-23 2005-09-29 F.Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
CN1942449A (zh) * 2004-04-15 2007-04-04 弗·哈夫曼-拉罗切有限公司 制备哒嗪酮化合物的方法
GB0423042D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Chemical process
US7700640B2 (en) * 2004-10-16 2010-04-20 Astrazeneca Ab Process for making phenoxy benzamide compounds
EP1863777A1 (en) * 2005-03-24 2007-12-12 F.Hoffmann-La Roche Ag 1,2,4 -triazole-5-one compounds as heterocyclic reverse transcriptase inhibitors
NZ575512A (en) 2005-07-09 2009-11-27 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
BRPI0613754B8 (pt) * 2005-07-21 2021-05-25 Hoffmann La Roche compostos, éster de um composto, composições farmacêuticas que compreendem o composto, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por análogos de hormônio de tireóide e utilização dos compostos
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
ES2317584T3 (es) 2005-09-30 2009-04-16 F. Hoffmann-La Roche Ag Inhibidores de nnrt.
WO2007045573A1 (en) 2005-10-19 2007-04-26 F. Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
GB0610680D0 (en) 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
CL2007002105A1 (es) * 2006-07-21 2008-02-22 Hoffmann La Roche Compuestos derivados de 2-[3-(3-cianofenoxi)(fenoxi o fenilsulfanil)]-n-fenil acetamida, inhibidores de la transcriptasa inversa del vih; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar u
BRPI0715193A2 (pt) * 2006-08-16 2013-10-01 Hoffmann La Roche inibidores nço-nucleosÍdicos da transcriptase reversa
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
WO2008119662A1 (en) 2007-03-29 2008-10-09 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
AU2008235549A1 (en) * 2007-04-09 2008-10-16 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
RS52518B (sr) 2007-04-23 2013-04-30 Janssen Pharmaceutica N.V. Derivati 4-alkoksipiridazina kao brzo disocirajući dopamin 2 receptorski antagonisti
RU2489431C2 (ru) 2007-04-23 2013-08-10 Янссен Фармацевтика Н.В. Тиа(диа)золы как быстро диссоциирующие антагонисты рецептора допамина 2
AU2008257771B2 (en) * 2007-05-30 2015-02-19 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
JP2010530863A (ja) * 2007-06-22 2010-09-16 エフ．ホフマン−ラ ロシュ アーゲー 非ヌクレオシド逆転写酵素阻害剤としての尿素及びカルバマート誘導体
EP2220073B1 (en) 2007-11-15 2014-09-03 MSD Italia S.r.l. Pyridazinone derivatives as parp inhibitors
KR20100088142A (ko) 2007-11-20 2010-08-06 머크 샤프 앤드 돔 코포레이션 비-뉴클레오사이드 역전사효소 억제제
US8877816B2 (en) * 2007-11-21 2014-11-04 Decode Genetics Ehf 4-(or 5-) substituted catechol derivatives
CN101903382B (zh) * 2007-12-21 2012-11-28 弗·哈夫曼-拉罗切有限公司 杂环抗病毒化合物
LT2307374T (lt) 2008-07-31 2017-04-25 Janssen Pharmaceutica Nv Piperazin-1-il-trifluormetil-pakeistieji piridinai kaip greitai disocijuojantys dopamino 2 receptoriaus antagonistai
BRPI0919282A2 (pt) 2008-10-02 2017-03-28 Asahi Kasei Pharma Corp composto, composição farmacêutica, inibidor de ikkb, método para inibir ikkb, métodos para prevenir e/ou tratar uma doença ou sintoma associado com nf-kb, uma doença ou sintoma associado com ikkb, e uma doença ou sintoma associado com reação inflamatória aguda ou crônica em mamíferos
EP2552902B1 (en) 2010-03-30 2015-03-11 Merck Canada Inc. Non-nucleoside reverse transcriptase inhibitors
CN102731410B (zh) * 2012-07-06 2014-07-30 山东大学 一种哒嗪类hiv-1逆转录酶抑制剂的制备与应用
ES3053122T3 (en) 2012-09-17 2026-01-19 Madrigal Pharmaceuticals Inc Thyroid hormone analogs
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
MX2016012915A (es) 2014-04-01 2016-12-07 Merck Sharp & Dohme Profarmacos de inhibidores de la transcriptasa inversa del virus de la inmunodeficiencia humana (vih).
DE102015011861B4 (de) 2015-09-10 2018-03-01 Rudolf Schindler Neue cyclische Carboxamide als NMDA NR2B Rezeptor Inhibitoren
EP3528817B1 (en) 2016-10-18 2022-05-25 Madrigal Pharmaceuticals, Inc. Methods of treating liver disorders or lipid disorders with a thr-beta agonist
CN109053693B (zh) * 2018-09-20 2021-02-05 顺毅股份有限公司 哒嗪胺类化合物的制备及其应用
WO2020131597A1 (en) 2018-12-18 2020-06-25 Merck Sharp & Dohme Corp. Pyrimidone derivatives as selective cytotoxic agents against hiv infected cells
KR20220030256A (ko) * 2019-07-01 2022-03-10 아센타위츠 파마슈티컬즈 리미티드 Akr1c3 저해제 및 이의 의학적 용도
CN116003253A (zh) * 2022-12-31 2023-04-25 上海试四化学品有限公司 一种三氟苯嘧啶中间体2-[3-(三氟甲基)苯基]丙二酸二甲酯的制备方法
US12377104B1 (en) 2024-02-06 2025-08-05 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease
WO2026042788A1 (ja) * 2024-08-20 2026-02-26 塩野義製薬株式会社 複素環誘導体

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4949314A (en) 1966-08-16 1990-08-14 The United States Of America As Represented By The Secretary Of The Navy Method and means for increasing echo-ranging-search rate
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4780480A (en) 1983-07-14 1988-10-25 Syntex (U.S.A.) Inc. Aroyl benzofuran and benzothiophene acetic and propionic acids
GB8327880D0 (en) 1983-10-18 1983-11-16 Ajinomoto Kk Saccharomyces cerevisiae
US4530787A (en) 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4569790A (en) 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US4604377A (en) 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
IL76360A0 (en) 1984-09-26 1986-01-31 Takeda Chemical Industries Ltd Mutual separation of proteins
US4752585A (en) 1985-12-17 1988-06-21 Cetus Corporation Oxidation-resistant muteins
GB8501372D0 (en) 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
US4748234A (en) 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
AU622926B2 (en) 1988-09-09 1992-04-30 Nippon Kayaku Kabushiki Kaisha Pyrimidine or purine cyclobutane derivatives
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5925643A (en) 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
IL106507A (en) 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US5783593A (en) 1993-11-04 1998-07-21 Abbott Laboratories Inhibitors of squalene synthetase and protein farnesyltransferase
US5489697A (en) 1994-08-03 1996-02-06 Medichem Research, Inc. Method for the preparation of (+)-calanolide A and intermediates thereof
EP0786455B1 (en) 1994-09-26 2003-12-03 Shionogi & Co., Ltd. Imidazole derivative
HUP9802078A3 (en) 1995-02-10 1999-04-28 Smithkline Beecham Corp Use of lck sh2 specific compounds to treat autoimmune diseases and allograft rejection
WO1996025171A1 (en) 1995-02-16 1996-08-22 F.Hoffmann-La Roche Ag Inhibition of angiogenesis using interleukin-12
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
IL117574A0 (en) 1995-04-03 1996-07-23 Bristol Myers Squibb Co Processes for the preparation of cyclobutanone derivatives
EP0871436A4 (en) 1995-06-30 1999-10-20 Smithkline Beecham Corp USE OF STAT 6 SH2 DOMAINE-SPECIFIC COMPOUNDS FOR TREATING ALLERGIC REACTIONS
EP0835104A4 (en) 1995-06-30 1999-10-20 Smithkline Beecham Corp USE OF STAT 5 SH2 DOMAINE SPECIFIC COMPOUNDS TO PROMOTE ERYTHROPOSIS
CA2205757C (en) 1996-05-30 2006-01-24 F. Hoffmann-La Roche Ag Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii)
ID27502A (id) * 1998-04-27 2001-04-12 Ct Nat De La Rech Scient Cs Turunan-turunan 3-(amino-atau aminoalkil) piridinon dan penggunannya untuk pengobatan penyakit-penyakit yang berkaitan dengan hiv
WO2001085670A1 (en) 2000-05-12 2001-11-15 Kissei Pharmaceutical Co., Ltd. Malonanilic acid derivatives, medicinal compositions containing the same and use thereof
GB0024795D0 (en) * 2000-10-10 2000-11-22 Hoffmann La Roche Pyrazole derivatives for the treatment of viral diseases
ES2283532T3 (es) 2001-04-10 2007-11-01 Pfizer, Inc. Derivados de pirazol para tratar el vih.
JPWO2002100833A1 (ja) 2001-06-12 2004-09-24 住友製薬株式会社 Ｒｈｏキナーゼ阻害剤

Also Published As

Publication number Publication date
AR043674A1 (es) 2005-08-03
EP1608629A1 (en) 2005-12-28
US7189718B2 (en) 2007-03-13
WO2004085406A1 (en) 2004-10-07
US20040198736A1 (en) 2004-10-07
MXPA05010081A (es) 2005-11-23
KR20050119652A (ko) 2005-12-21
RU2344128C2 (ru) 2009-01-20
CA2518823A1 (en) 2004-10-07
AU2004224191A1 (en) 2004-10-07
JP4485520B2 (ja) 2010-06-23
CN1764649A (zh) 2006-04-26
JP2006521310A (ja) 2006-09-21
TW200505453A (en) 2005-02-16
CN100469769C (zh) 2009-03-18
RU2005132630A (ru) 2006-07-27

Similar Documents

Publication Publication Date Title
BRPI0408704A (pt) benzil-piridazinonas como inibidores de transcriptase reversa
BRPI0408767A (pt) inibidores de transcriptase reversa não-nucleosìdeos i para o tratamento de doenças mediadas pelo hiv
BRPI0407591A (pt) inibidores de transcriptase reversa de não-nucleosìdeo
BR0208811A (pt) Derivados de pirazol para tratamento de hiv
BR0208907A (pt) Composto uso de um composto, composição farmacêutica, métodos para a terapia da dor em um animal de sangue quente e para a redução seletiva de uma porção nitro orto para um substituinte amino em um anel fenila ou piridila de um composto.
BR0316081A (pt) Derivados de 2-piridona como inibidores de elastase de neutrófilo
BR0209267A (pt) Pirimidinas fundidas como antagonistas do fator de liberação de corticotropina (crf)
BR0315912A (pt) Compostos pirimìdicos com atividade antiproliferativa (ii)
BR0313041A (pt) Compostos; composições farmacêuticas; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação dos receptores de cb1; e uso de compostos
BR0312271A (pt) compostos, composições e seus usos para o tratamento de infecções por flaviviridae
BR0210350A (pt) Nucleosìdeos 4'-substituìdos
BR0212378A (pt) Inibidores de 17beta-hidroxiesteróide desidrogenase tipo 3 para o tratamento de doenças dependentes de androgênio
BRPI0215312B8 (pt) composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto
NI200700102A (es) Derivados de indol tetraciclicos como agentes antiviricos
ATE402174T1 (de) Imidazopyridinderivate als kinaseinhibitoren
BRPI0414548A8 (pt) derivados de 2-piridona como inibidores de elastase de neutrófilo e seu uso
BRPI0414570A (pt) derivados de 2-piridona como inibidores de elastase de neutrófilo e seu uso
ECSP067076A (es) Derivados de pirimidina urea como inhibidores de la quinasa
NO20010743L (no) Antivirale indoloksoacetyl-piperazin-derivater
BRPI0407976A (pt) tetrahidroisoquinolinas substituìdas em 2,5 e 2,6 para uso como moduladores de 5-ht6
BRPI0514032A (pt) composto, sais farmaceuticamente aceitáveis do mesmo, diastereÈmeros, enanciÈmeros ou misturas do mesmo, uso de um composto, composição farmacêutica, método para a terapia de depressão em um animal de sangue quente, e, processo para preparar um composto
EA200600227A1 (ru) Замещённые арилтиомочевины, применимые в качестве ингибиторов репликации вирусов
BRPI0510059B8 (pt) inibidores da transcriptase reversa não-nucleosídica e seus usos
BRPI0515885A (pt) derivados de ftalazinona, sua preparação e uso como agentes farmacêuticos
BRPI0409884A (pt) compostos, composições farmacêuticas, método para o tratamento ou porfilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.